Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| LGD-4033 (Ligandrol) | RAD-140 (Testolone) | |
|---|---|---|
| Category | SARMs | SARMs |
| Standard Dose | Research indicates 5-10 mg daily orally for 8-12 weeks. Phase 1 data showed significant lean mass gains at 1 mg/day. | Research indicates 10-20 mg daily orally for 8-12 weeks. Phase 1 clinical trial (oncology) identified 100 mg as the maximum tolerated dose. |
| Timing | Once daily, consistent timing. Half-life approximately 24-36 hours. No food timing requirements. | Once daily, consistent timing. Very long half-life (~60 hours) means stable plasma levels even with once-daily dosing. Morning preferred. |
| Cycle Duration | 8-12 week cycles maximum. PCT strongly recommended after all but the shortest/lowest-dose cycles. | 8-12 week cycles. PCT mandatory due to significant HPG axis suppression. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
LGD-4033 is a potent nonsteroidal selective androgen receptor modulator with high AR binding affinity (Ki of approximately 1 nM). It demonstrates strong anabolic activity in muscle and bone with significantly reduced androgenic activity in prostate tissue, achieving an anabolic-to-androgenic ratio of approximately 10:1. LGD-4033 activates the AR with full agonist efficacy in muscle, upregulating the PI3K/Akt/mTOR pathway for protein synthesis and satellite cell recruitment. It produces dose-dependent suppression of SHBG, total testosterone, LH, and FSH, indicating significant HPG axis suppression even at low doses.
Research indicates 5-10 mg daily orally for 8-12 weeks. Phase 1 data showed significant lean mass gains at 1 mg/day.
Once daily, consistent timing. Half-life approximately 24-36 hours. No food timing requirements.
8-12 week cycles maximum. PCT strongly recommended after all but the shortest/lowest-dose cycles.
RAD-140 is a potent nonsteroidal SARM with high oral bioavailability and selectivity for muscle and bone AR over prostate. It acts as a full agonist at the AR in muscle tissue, promoting nitrogen retention and protein synthesis via mTOR/p70S6K pathway activation. RAD-140 also demonstrates neuroprotective properties, acting against beta-amyloid-induced neurotoxicity through AR-mediated MAPK/ERK signaling. Preclinical data show greater anabolic potency than testosterone propionate at equivalent doses with significantly reduced prostate stimulation.
Research indicates 10-20 mg daily orally for 8-12 weeks. Phase 1 clinical trial (oncology) identified 100 mg as the maximum tolerated dose.
Once daily, consistent timing. Very long half-life (~60 hours) means stable plasma levels even with once-daily dosing. Morning preferred.
8-12 week cycles. PCT mandatory due to significant HPG axis suppression.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →